References
- Celli BR, Locantore N, Yates J, for the ECLIPSE Investigators, et al. Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;185(10):1065–1072. DOI:https://doi.org/10.1164/rccm.201110-1792OC
- Lapolla A, Bonomo M, Dalfra MG, et al. Prepregnancy BMI influences maternal and fetal outcomes in women with isolated gestational hyperglycaemia: a multicentre study. Diabetes Metab. 2010;36(4):265–270. DOI:https://doi.org/10.1016/j.diabet.2010.01.008
- Zuur-Telgen MC, Brusse-Keizer MG, Vandervalk PD, et al. Stable state MR-proadrenomedullin level is a strong predictor for mortality in COPD patients. Chest. 2014;145(3):534–541. DOI:https://doi.org/10.1378/chest.13-1063
- Vizza CD, Letizia C, Sciomer S, et al. Increased plasma levels of adrenomedullin, a vasoactive peptide, in patients with end-stage pulmonary disease. Regul Pept. 2005;124(1-3):187–193. DOI:https://doi.org/10.1016/j.regpep.2004.07.021
- Stolz D, Christ-Crain M, Morgenthaler NG, et al. Plasma pro-adrenomedullin but not plasma pro-endothelin predicts survival in exacerbations of COPD. Chest. 2008;134(2):263–272. DOI:https://doi.org/10.1378/chest.08-0047
- Grolimund E, Kutz A, Marlowe RJ, ProHOSP Study Group, et al. Long-term prognosis in COPD Exacerbation: Role of biomarkers, clinical variables and exacerbation type. COPD. 2015;12(3):295–305. DOI:https://doi.org/10.3109/15412555.2014.949002
- Linscheid P, Seboek D, Zulewski H, et al. Autocrine/paracrine role of inflammation-mediated calcitonin gene-related peptide and adrenomedullin expression in human adipose tissue. Endocrinology. 2005;146(6):2699–2708. DOI:https://doi.org/10.1210/en.2004-1424
- Yoshibayashi M, Kamiya T, Kitamura K, et al. Plasma levels of adrenomedullin in primary and secondary pulmonary hypertension in patients <20 years of age. Am J Cardiol. 1997;79:1556–1558.
- Cheung BM, Hwang IS, Li CY, et al. Increased adrenomedullin expression in lungs in endotoxaemia. J Endocrinol. 2004;181(2):339–345. DOI:https://doi.org/10.1677/joe.0.1810339
- Brusse-Keizer M, Zuur-Telgen M, van der Palen J, et al. Adrenomedullin optimises mortality prediction in COPD patients. Respir Med. 2015;109(6):734–742. DOI:https://doi.org/10.1016/j.rmed.2015.02.013
- Stolz D, Kostikas K, Blasi F, et al. Adrenomedullin refines mortality prediction by the BODE index in COPD: the "BODE-A" index. Eur Respir J. 2014;43(2):397–408. DOI:https://doi.org/10.1183/09031936.00058713
- Miller BE, Tal-Singer R, Rennard SI, et al. Plasma fibrinogen qualification as a drug development tool in chronic obstructive pulmonary disease. Perspective of the chronic obstructive pulmonary disease biomarker qualification consortium. Am J Respir Crit Care Med. 2016;193(6):607–613. DOI:https://doi.org/10.1164/rccm.201509-1722PP
- Haidaris PJ. Induction of fibrinogen biosynthesis and secretion from cultured pulmonary epithelial cells. Blood. 1997;89(3):873–882.
- Simpson-Haidaris PJ, Courtney MA, Wright TW, et al. Induction of fibrinogen expression in the lung epithelium during Pneumocystis carinii pneumonia. Infect Immun. 1998;66(9):4431–4439. DOI:https://doi.org/10.1128/IAI.66.9.4431-4439.1998
- Duvoix A, Dickens J, Haq I, et al. Blood fibrinogen as a biomarker of chronic obstructive pulmonary disease. Thorax. 2013;68(7):670–676. DOI:https://doi.org/10.1136/thoraxjnl-2012-201871
- Groenewegen KH, Postma DS, Hop WC, COSMIC Study Group, et al. Increased systemic inflammation is a risk factor for COPD exacerbations. Chest. 2008;133(2):350–357. DOI:https://doi.org/10.1378/chest.07-1342
- Hurst JR, Vestbo J, Anzueto A, Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12):1128–1138. DOI:https://doi.org/10.1056/NEJMoa0909883
- Danesh J, Lewington S, Thompson SG, Fibrinogen Studies Collaboration, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA. 2005;294(14):1799–1809. DOI:https://doi.org/10.1001/jama.294.14.1799
- Mannino DM, Tal-Singer R, Lomas DA, et al. Plasma fibrinogen as a Biomarker for Mortality and Hospitalized Exacerbations in People with COPD. Chronic Obstr Pulm Dis. 2015;2(1):23–34.
- Mannino DM, Valvi D, Mullerova H, et al. Fibrinogen, COPD and mortality in a nationally representative U.S. cohort. COPD. 2012;9(4):359–366. DOI:https://doi.org/10.3109/15412555.2012.668249
- Sand JM, Leeming DJ, Byrjalsen I, et al. High levels of biomarkers of collagen remodeling are associated with increased mortality in COPD - results from the ECLIPSE study. Respir Res. 2016;17(1):125. DOI:https://doi.org/10.1186/s12931-016-0440-6
- Vestbo J, Edwards LD, Scanlon PD, ECLIPSE Investigators, et al. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med. 2011;365(13):1184–1192. DOI:https://doi.org/10.1056/NEJMoa1105482
- Miller J, Edwards LD, Agusti A, Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators, et al. Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respir Med. 2013;107(9):1376–1384. DOI:https://doi.org/10.1016/j.rmed.2013.05.001
- Keene JD, Jacobson S, Kechris K, COPDGene and SPIROMICS Investigators ‡, et al. Biomarkers predictive of Exacerbations in the SPIROMICS and COPDGene Cohorts. Am J Respir Crit Care Med. 2017;195(4):473–481. DOI:https://doi.org/10.1164/rccm.201607-1330OC
- Zemans RL, Jacobson S, Keene J, et al. Multiple biomarkers predict disease severity, progression and mortality in COPD. Respir Res. 2017;18(1):117. DOI:https://doi.org/10.1186/s12931-017-0597-7
- Mendy A, Forno E, Niyonsenga T, et al. Blood biomarkers as predictors of long-term mortality in COPD. Clin Respir J. 2018;12(5):1891–1899. DOI:https://doi.org/10.1111/crj.12752
- Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease [GOLD] 2011; 2011. Available from: http://www.goldcopd.org/.
- Telgen MC, Brusse-Keizer MG, van der Valk P, et al. Impact on clinical decision making of quality control standards applied to sputum analysis in COPD. Respir Med. 2011;105(3):371–376. DOI:https://doi.org/10.1016/j.rmed.2010.10.009
- Mahler DA, Wells CK. Evaluation of clinical methods for rating dyspnea. Chest. 1988;93(3):580–586. DOI:https://doi.org/10.1378/chest.93.3.580
- Kort S, Ter Huurne K, van der Palen J, et al. Quality of life and adherence to inhaled corticosteroids and tiotropium in COPD are related. COPD. 2016;11:1679–1688. DOI:https://doi.org/10.2147/COPD.S107303
- Morgenthaler NG, Struck J, Alonso C, et al. Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay. Clin Chem. 2005;51(10):1823–1829. DOI:https://doi.org/10.1373/clinchem.2005.051110
- Zuur-Telgen M, VanderValk P, van der Palen J, et al. Stable state proadrenomedullin level in COPD Patients: A Validation Study. COPD. 2017;14(2):219–227. DOI:https://doi.org/10.1080/15412555.2016.1250254
- Nam B-H, D’Agostino R, et al. The area under the ROC curve. In: Huber-Carol C, Balakrishnan N, Nikulin MS, editors. Goodness-of-fit tests and model validity. Boston: Birkhäuser; 2002. p. 273–277.
- DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44(3):837–845.
- Polatli M, Cakir A, Cildag O, et al. Microalbuminuria, von Willebrand factor and fibrinogen levels as markers of the severity in COPD exacerbation. J Thromb Thrombolysis. 2008;26(2):97–102. DOI:https://doi.org/10.1007/s11239-007-0073-1
- Alessandri C, Basili S, Violi F, et al. Hypercoagulability state in patients with chronic obstructive pulmonary disease. Chronic Obstructive Bronchitis and Haemostasis Group. Thromb Haemost. 1994;72(3):343–346.
- Mannino DM, Ford ES, Redd SC. Obstructive and restrictive lung disease and markers of inflammation: data from the Third National Health and Nutrition Examination. Am J Med. 2003;114(9):758–762. DOI:https://doi.org/10.1016/S0002-9343(03)00185-2
- Wedzicha JA, Seemungal TA, MacCallum PK, et al. Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levels. Thromb Haemost. 2000;84(8):210–215. DOI:https://doi.org/10.1055/s-0037-1613998
- Saldias PF, Diaz PO, Dreyse DJ, et al. [Etiology and biomarkers of systemic inflammation in mild to moderate COPD exacerbations]. Rev Med Chil. 2012;140(1):10–18.
- Valipour A, Schreder M, Wolzt M, et al. Circulating vascular endothelial growth factor and systemic inflammatory markers in patients with stable and exacerbated chronic obstructive pulmonary disease. Clin Sci (Lond). 2008;115(7):225–232. DOI:https://doi.org/10.1042/CS20070382
- Stockley RA, Halpin DMG, Celli BR, et al. Chronic obstructive pulmonary disease biomarkers and their interpretation. Am J Respir Crit Care Med. 2019 May;199(10):1195–1204. DOI:https://doi.org/10.1164/rccm.201810-1860SO
- Barnes PJ. Cellular and molecular mechanisms of chronic obstructive pulmonary disease. Clin Chest Med. 2014;35(1):71–86. DOI:https://doi.org/10.1016/j.ccm.2013.10.004
- Koutsokera A, Stolz D, Loukides S, et al. Systemic biomarkers in exacerbations of COPD: the evolving clinical challenge. Chest. 2012;141(2):396–405. DOI:https://doi.org/10.1378/chest.11-0495